Evidence map›Paper›PMID 30290161›Full record

ReviewMechanisms of ageing and development2019

Modelling physical resilience in ageing mice.

Markus Schosserer, Gareth Banks, Soner Dogan, Peter Dungel, Adelaide Fernandes, Darja Marolt Presen, Ander Matheu, Marcin Osuchowski, Paul Potter, Coral Sanfeliu and 3 more

Abstract readReview
In one paragraph

Review in Mechanisms of ageing and development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Markus SchossererUniversity of Natural Resources and Life Sciences, Vienna, Department of Biotechnology, Vienna, Austria.
Gareth BanksMammalian Genetics Unit, MRC Harwell Institute, Harwell Campus, Oxfordshire, OX11 0RD, United Kingdom.
Soner DoganDepartment of Medical Biology, School of Medicine, Yeditepe University, Istanbul, Turkey.
Peter DungelLudwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Vienna, Austria.
Adelaide FernandesNeuron-Glia Biology in Health and Disease, iMed.ULisboa, Research Institute for Medicines, Department of Biochemistry and Human Biology, Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal.
Darja Marolt PresenLudwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Vienna, Austria.
Ander MatheuOncology Department, Biodonostia Research Institute, San Sebastián, Spain.
Marcin OsuchowskiLudwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Vienna, Austria.
Paul PotterMammalian Genetics Unit, MRC Harwell Institute, Harwell Campus, Oxfordshire, OX11 0RD, United Kingdom.
Coral SanfeliuInstitute of Biomedical Research of Barcelona (IIBB) CSIC, IDIBAPS, CIBERESP, Barcelona, Spain.
Bilge Guvenc TunaDepartment of Medical Biophysics, School of Medicine, Yeditepe University, Istanbul, Turkey.
Isabel Varela-Nieto"Alberto Sols" Biomedical Research Institute CSIC-UAM, Madrid, Spain.
Ilaria BellantuonoMRC/Arthritis Research-UK Centre for Integrated Research into Musculoskeletal Ageing (CIMA), Department of Oncology and Metabolism, The Medical School, Beech Hill Road, Sheffield, S10 2RX, United Kingdom. Electronic address: i.bellantuono@shef.ac.uk.

Funding

Austrian Science Fund FWF P 30623Medical Research Council MC_U142684172Medical Research Council MC_U142684173Medical Research Council MR/P020941/1
6 · The paper itself

Abstract

Geroprotectors, a class of drugs targeting multiple deficits occurring with age, necessitate the development of new animal models to test their efficacy. The COST Action MouseAGE is a European network whose aim is to reach consensus on the translational path required for geroprotectors, interventions targeting the biology of ageing. In our previous work we identified frailty and loss of resilience as a potential target for geroprotectors. Frailty is the result of an accumulation of deficits, which occurs with age and reduces the ability to respond to adverse events (physical resilience). Modelling frailty and physical resilience in mice is challenging for many reasons. There is no consensus on the precise definition of frailty and resilience in patients or on how best to measure it. This makes it difficult to evaluate available mouse models. In addition, the characterization of those models is poor. Here we review potential models of physical resilience, focusing on those where there is some evidence that the administration of acute stressors requires integrative responses involving multiple tissues and where aged mice showed a delayed recovery or a worse outcome then young mice in response to the stressor. These models include sepsis, trauma, drug- and radiation exposure, kidney and brain ischemia, exposure to noise, heat and cold shock.

Indexed as

Models, BiologicalAgingAnimalsMiceAgeingFrailtyIntervention testingMouse modelsPhysical resilienceStress recovery

Identifiers

PMID30290161
PMCPMC6445352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.